BACKGROUND Multiparametric flow cytometry (MFC) was recently reported to be a helpful additional tool in the diagnosis of myelodysplastic syndromes (MDS). However, numerous aberrancies have been reported that makes their evaluation difficult as part of a routine diagnosis. METHODS Here, we validated a 1-tube panel for the evaluation of granulocytic and monocytic maturation by MFC and correlated our findings with diagnosis and prognosis of MDS. A total of 251 samples with MDS suspicion were prospectively analyzed and compared to an internal reference database leading to the calculation of the Diff score. RESULTS The associated specificity and sensitivity values of this scoring system were 92.1% and 60.4% in a first learning cohort and 96.7% and 65.2% in a second independent validation cohort. The combination of the Diff score with the concomitantly calculated Ogata score increased the sensitivity to 74.2% and 78.3% in the learning and validation cohorts, respectively. Finally, a normal Diff score in MDS patients was associated with a significant prolonged progression-free survival. CONCLUSIONS Taken together, the present data indicate that our strategy is a sensitive and specific MFC tool for the diagnosis of MDS-related cytopenia(s) which could be also useful for predicting evolution of these diseases.

中文翻译：

---

多参数流式细胞术对粒细胞和单核细胞的表型景观：对MDS患者诊断和预后的1-tube面板策略的前瞻性研究。

背景技术最近报道了多参数流式细胞术（MFC）是诊断骨髓增生异常综合症（MDS）的有用的附加工具。然而，已经报道了许多畸变，这使得它们的评估难以作为常规诊断的一部分。方法在这里，我们验证了一个1管面板，用于通过MFC评估粒细胞和单核细胞的成熟度，并将我们的发现与MDS的诊断和预后相关联。前瞻性分析了总共251个具有MDS怀疑的样本，并将其与内部参考数据库进行比较，从而计算出Diff得分。结果该评分系统的相关特异性和敏感性值在第一次学习队列中分别为92.1％和60.4％，在第二次独立验证队列中分别为96.7％和65.2％。在学习和验证队列中，将Diff评分与随之而来的Ogata评分相结合可将敏感性分别提高到74.2％和78.3％。最后，MDS患者的正常Diff评分与长期无进展生存期显着相关。结论综上所述，目前的数据表明我们的策略是用于诊断MDS相关血细胞减少症的灵敏且特异的MFC工具，也可用于预测这些疾病的进展。